Paradoxical relationship between acetylator phenotype and amonafide toxicity.

Abstract excerpt

Patients receiving the investigational antineoplastic agent amonafide underwent prospective determination of acetylator phenotype with use of caffeine as a test drug. Fast acetylators of caffeine had significantly greater toxicity (myelosuppression) after amonafide treatment than slow acetylators, presumably because of greater conversion of amonafide to the active acetylated metabolite. Furthermore, the estimated...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acetylation
• Share to Adenine
• Share to Antineoplastic Agents